Scholar Rock Holding Corp(SRRK)Finding the best opportunities to buy and sell stocks daily.
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 69 full-time employees. The firm is engaged in the development of monoclonal antibodies for treatment of diseases, such as neuromuscular disorders, cancer, fibrosis, and anemia. The firm's lead product candidate is SRK-015 that is in its pre-clinical stage of development. SRK-015 is a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle. The company is used to treat spinal muscular atrophy (SMA). The firm also develops other antibody programs that include TGF?1 and BMP6. The TGF?1 antibody program is focused on the development of antibodies that are specific inhibitors of TGF?1 members.
All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.